This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
8/22/2024
Jonathan
Host/Interviewer
Welcome to today's live report from Modus Therapeutics, where we have invited CEO John Oed to go through the development during the second quarter of 2024. Those of you who are here live can ask questions directly in the chat to John, and I will pick up where after. I think that's appropriate. Jag ska också säga att den länk som fanns med i dagens pressmeddelande i anslutning till rapporten inte fungerade som den skulle så förhoppningsvis hittar ni hit ändå. Och så får vi vara duktiga på att sprida den här intervjun vidare i efterhand helt enkelt. Välkommen John till att börja med.
John Oed
CEO
Tack Jonathan. And before we start talking, I would just like to say that I have had a problem with hoarseness and coughing the last few weeks, so if there is any problem with hearing what I say at any time, I apologize for that.
Jonathan
Host/Interviewer
Shall we start with the result for the period? Is there anything to comment on there? It is a result of minus 4.8 million, somewhat lower than the corresponding period last year. Is this due to increased research and development costs or what lies behind the figure?
You're reading a preview of the MODTX.ST Q2 2024 earnings call.
Free account.
Disclaimer